Alphamab Oncology (Stock Code: 9966) announced on November 7, 2025, that its board of directors approved an on-market share repurchase of up to HK$30 million. The authorization stems from a previously granted Share Repurchase Mandate endorsed at the annual general meeting on June 12, 2025, which remains valid until the conclusion of the next annual general meeting or until varied or revoked by shareholders.

According to the announcement, the company intends to fund the repurchases using existing available cash. Conceivable share repurchases will not exceed a price more than 5% above the average closing price of its shares as quoted over the five trading days prior to each transaction. The board believes that repurchasing shares reflects confidence in the company’s outlook and prospects.

As of the announcement’s date, Alphamab Oncology has repurchased 1,681,000 shares under the same mandate, which are being held as treasury shares. The company notes that future repurchase activities will be contingent on prevailing market conditions, with no guarantee regarding timing, quantity, or price.